Merck

$72.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.00 (-2.68%) Today
+$0.11 (+0.15%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Merck and other stocks, options, and ETFs commission-free!

About MRK

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ. The listed name for MRK is Merck & Co., Inc.

CEO
Kenneth C. Frazier
Employees
71,000
Headquarters
Kenilworth, New Jersey
Founded
1891
Market Cap
183.53B
Price-Earnings Ratio
26.11
Dividend Yield
3.42
Average Volume
10.55M
High Today
$74.63
Low Today
$72.54
Open Price
$74.46
Volume
16.84M
52 Week High
$87.80
52 Week Low
$65.25

MRK News

MarketWatchFeb 26

Merck & Co. Inc. stock underperforms Friday when compared to competitors

Shares of Merck & Co. Inc. MRK, -2.68% slipped 2.68% to $72.62 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&
BenzingaFeb 26

Why Pandion Therapeutics Stock Shot Up 133% Today

Pandion Therapeutics Inc (NASDAQ: PAND) shares closed over 133% higher today. What Happened: Pandion — a developer of novel therapeutics targeting autoimmune d
ReutersFeb 25

Merck says FDA requires more data on its COVID-19 drug

NEW YORK, Feb 25 (Reuters) - Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in ord

MRK Earnings

$0.00
$0.58
$1.16
$1.74
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Available Apr 29, Pre-Market

You May Also Like

SIEN

More MRK News

BenzingaFeb 25

Why Merck Is Buying Autoimmune Disease Drug Company Pandion For $1.85B

Merck & Co., Inc. (NYSE: MRK) is making another big-ticket buy, this time to expand its presence in the autoimmune disease market. What Happened: Large-cap bio
ReutersFeb 25

Merck to buy drug developer Pandion Therapeutics for $1.85 billion

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey (Reuters) - Merck & Co Inc said on Thursday it would buy drug devel
MarketWatchFeb 25

Merck to buy Pandion Therapeutics for 134% premium

Merck & Co. MRK, +0.04% announced an agreement Thursday to buy Pandion Therapeutics Inc. PAND, +2.07% in a deal valued at $1.85 billion. Under terms of the deal
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure